CN1113386A - Substituted kynurenines, a process for their preparation, and use as medicaments - Google Patents

Substituted kynurenines, a process for their preparation, and use as medicaments Download PDF

Info

Publication number
CN1113386A
CN1113386A CN94190583A CN94190583A CN1113386A CN 1113386 A CN1113386 A CN 1113386A CN 94190583 A CN94190583 A CN 94190583A CN 94190583 A CN94190583 A CN 94190583A CN 1113386 A CN1113386 A CN 1113386A
Authority
CN
China
Prior art keywords
amino
compound
formula
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94190583A
Other languages
Chinese (zh)
Inventor
罗伯特·施瓦茨
马里奥·瓦拉西
阿图罗·D-托尔
卡梅拉·斯佩谢拉
艾伯特·布兰切特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharMetrix Corp
University of Maryland at Baltimore
Original Assignee
PharMetrix Corp
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharMetrix Corp, University of Maryland at Baltimore filed Critical PharMetrix Corp
Publication of CN1113386A publication Critical patent/CN1113386A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Luminescent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) wherein R is halogen, C1-C6 alkyl, C5-C7 cycloalkyl, phenyl-C1-C4 alkyl, C1-C6 alkoxy, C6-C10 aryloxy, phenyl-C1-C4 alkoxy or trifluoromethyl, and R1 is hydroxy, C1-C6 alkoxy, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxylamino, C1-C4 alkoxyamino or benzyloxyamino.

Description

Substituted kynurenines, a process for their preparation, and use as medicaments
The present invention relates to new medical use and some new compounds of some compound, and the method and the pharmaceutical composition that contains these compounds that prepare these compounds.
Especially, the present invention relates to be used for the treatment of the compound that obstacle is known in the knowledge relevant with the brain aging process, this compounds is used as the kynurenine aminotransferase inhibitor of (being called KAT in the prior art).
These compounds as the KAT inhibitor can be identified by standard test, for example according to J.Neurochem., 57,533-540(1991), in the homogenate of murine brain, measure compound to suppressing the active ability of KAT, perhaps according to J.Neurochem., 52,1629-1636(1989) restraining effect that this compounds generates kynurenic acid (KYNA) is measured in the murine brain section that utilizes described in.
The catalysis of KAT energy is turned to the biosynthesizing of KYNA by kynurenine (KYN):
And KAT is the special material (J.Neurochem., 57,533-540,1991) of replying that the KYNA EC is regulated in the brain.
KYNA is effective excited amino acid (EAA) receptor antagonist, and it has extra high affinity (J.Neurochem., 52,1319-1328,1989) to the glycine regulatory site of N-methyl-D-aspartate (NMDA) receptor complex.
As naturally occurring brain meta-bolites (J.Neurochem., 51,177-180,1988 and Brain Res, 454,164-169,1988), KYNA may be as the reverse endogenous conditioning agent of brain L-glutamic acid function and work (Ann.N.Y.Acad.Sci., Vol.648, P.140-153,1992).
The EAA acceptor, particularly nmda receptor is known, its (J.C.Watkins and G.L. that in mammal brain, plays an important role, Collingridge-edits-, The NMDA receptor, Oxford University Press, Oxford, 1989, PP.242).For example, the activation of nmda receptor is to cognitive process, and for example learning and memory is important (J.C.Watkins and G.L.Collingridge-eds-, In:The NMDA receptor, Oxford University Press, Oxford, P.137～151,1989), it also is important (Trends Pharmacol.Sci. that brain is evolved, 11,290～296,1990).
Therefore, the decline of nmda receptor function is to the brain physiological function, and then whole organism is had adverse influence.The minimizing of the nmda receptor quantity that for example occurs in the brain of aging (Synapse, 6,388～343,1990) may the knowledge relevant with aging be known what the imbalance of function was associated.
In brain, the activity of the biosynthetic enzyme KAT of the concentration of KYNA and KYNA rise appreciably with age (Brain Res.558,1～5,1992 and Neurosci, Lett., 94,145～150,1988).The KAT inhibitor is by making the segmental increase of L-glutamic acid on the nmda receptor, to nmda receptor function insufficient and/or KAT is active and KYNA to measure unusual enhanced situation particularly useful.Therefore, they are to treatment and old and feeble relevant pathological manifestations, and for example, obstacle is known in the elderly's knowledge, comprises that attention and memory weaken and the phenomenon of having a sleepless night is particularly useful.
The KAT inhibitor also can be used for the treatment of brain function imbalance in term, brain function imbalance in term may with irregular relevant (the H.Baran and R.Schwarcz:Regional differences in the ontogenic pattern of KAT in the rat brain in the special type of characteristic area that postpartum, KAT evolved, Dev.Brain Res., in press).
Therefore a first aspect of the present invention comprises the application of KAT inhibitor aspect treatment brain function imbalance in term.
In specification sheets of the present invention, " treatment " speech comprises that " prophylactic treatment " reaches " obviously alleviating of symptom ".
According to the present invention, the specific compound that is used as the KAT inhibitor is that the 5-with following logical formula I replaces the kynurenine derivative:
Figure 941905837_IMG8
Wherein R is halogen, C 1-C 6Alkyl, C 5-C 7Cycloalkyl, phenyl-C 1-C 4Alkyl, C 1-C 6Alkoxyl group, C 6-C 10Aryloxy, phenyl C 1-C 4Alkoxyl group or trifluoromethyl;
R 1Be hydroxyl, C 1-C 6Alkoxyl group, amino, list-C 1-C 6Alkylamino, two-C 1-C 6Alkylamino, hydroxyl amino, C 1-C 4Alkoxy amino or benzyloxy amino.
The present invention also comprises the acceptable salt of medicine as the formula I compound of KAT inhibitor, and the possible isomer of the Individual existence of formula I representative or mixing existence.
The present invention also relates to some new compound of formula I compound representative.
As the compound of second purpose of the present invention, be compound with following general formula (IA):
Figure 941905837_IMG9
Wherein R is halogen, C 1-C 6Alkyl, C 5-C 7Cycloalkyl, phenyl-C 1-C 4Alkyl, C 1-C 6Alkoxyl group, C 6-C 10Aryloxy, phenyl C 1-C 4Alkoxyl group or trifluoromethyl;
R 1Be hydroxyl, C 1-C 6Alkoxyl group, amino, list-C 1-C 6Alkylamino, two-C 1-C 6Alkylamino, hydroxyl amino, C 1-C 4Alkoxy amino or benzyloxy amino.
Condition is:
(ⅰ) work as R 1Be that then this halogen was not a fluorine when hydroxyl and while, R was halogen; With
(ⅱ) work as R 1Be that hydroxyl and while R are C 1-C 6During alkyl, this C then 1-C 6Alkyl is not a methyl.
The medicinal acceptable salt that also comprises formula (IA) compound in second purpose of the present invention reaches the Individual existence of formula (IA) representative or mixes the whole possible isomer that exists, and is subjected to the restriction of above-mentioned condition equally.
In this manual, for above-mentioned formula I and (IA), various substituent features are as follows:
" halogen " represents Cl, Br, I or F, preferred Cl and Br.
" C 1-C 6Alkyl " comprise for example methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl-, the tertiary butyl, n-pentyl, isopentyl and n-hexyl, preferably methyl, ethyl, n-propyl or sec.-propyl.
" C 5-C 7Cycloalkyl " represent the monocyclic carbocyclic ring of 5～7 joints, preferably cyclopentyl or cyclohexyl.
" C 6-C 10Aryloxy " comprise for example phenoxy group and naphthyloxy; Phenoxy group preferably.
" phenyl-C 1-C 4Alkyl " representative contains the C of phenyl 1-C 4Alkyl, for example benzyl or 1-phenylethyl; Benzyl preferably.
" phenyl-C 1-C 4Alkoxyl group " representative contains the C of phenyl 1-C 4Alkoxyl group, for example benzyloxy or 1-phenyl ethoxy; Benzyloxy preferably.
" C 1-C 6Alkoxyl group " comprise, for example, methoxyl group, oxyethyl group, positive propoxy and isopropoxy; Methoxy or ethoxy preferably.
" C 1-C 6Alkylamino " comprise, for example, methylamino-, ethylamino, n-propylamine base, isopropylamino and n-butyl amine base; Methylamino-preferably.
" C 1-C 4Alkoxy amino " comprise, for example, methoxy amino, ethoxy amino, positive third oxygen amino and the different third oxygen amino; Methoxy amino preferably.
Formula I and (IA) compound have a unsymmetrical carbon, thereby they may exist with racemic mixture (enantiomorph) form of optical isomer, or exist with single optical isomer form.
Except as otherwise noted, formula I or (IA) the S configuration of the asymmetric center of compound be equivalent to the L type of natural kynurenine, otherwise the R configuration is equivalent to the D type of natural kynurenine.
Formula I or (IA) the medicinal acceptable salt of compound comprise and use the formed salt of medicinal acceptable acids, or mineral acid, for example hydrochloric acid, Hydrogen bromide, nitric acid or sulfuric acid or organic acid, for example citric acid, tartrate, toxilic acid, fumaric acid, methylsulfonic acid or ethyl sulfonic acid, perhaps, when formula I or compound (IA) contain acidic-group, for example during carbonyl, then form salt, for example basic metal with medicinal acceptable alkali, as sodium or potassium, alkaline-earth metal such as calcium or magnesium; Zinc or aluminium; Or for example aliphatic amine of organic bases such as methylamine, diethylamine, Trimethylamine, ethamine and heterocyclic amine such as pyridine.
The preferred compounds of the present invention is the compound by formula (IA) expression, its single isomer or isomer mixture, and medicinal acceptable salt, and wherein R is a halogen, C 1-C 6Alkyl or C 5-C 7Cycloalkyl; R 1It is hydroxyl; Condition is:
(ⅰ) when R is halogen, then this halogen is a fluorine not; With
(ⅱ) when R be C 1-C 6During alkyl, this C then 1-C 6Alkyl is not a methyl.
The special case of the preferred compound of above-mentioned formula (IA) has:
2-amino-4-(2-amino-5-chloro-phenyl-)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-ethylphenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-bromophenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-n-propyl phenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-isopropyl phenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-cyclohexyl phenyl)-4-oxo-butyric acid;
And the single isomer of above-claimed cpd or mixture of isomers and medicinal acceptable salt thereof.
Formula I of the present invention or compound (IA) can prepare according to following method:
1) makes the compound of formula II and chloro acetonitrile reaction and obtain the compound of formula III
Figure 941905837_IMG10
Wherein R such as formula I or (IA) in definition,
Figure 941905837_IMG11
Wherein the R definition as above.
2) compound of formula III and the sodium salt of diethyl kharophen propanedioic acid are reacted, obtain the compound of formula IV
Figure 941905837_IMG12
Wherein the R definition as above.
3) compound of formula IV is handled with concentrated hydrochloric acid, obtained R and define as above and R 1Be the formula I of hydroxyl or compound (IA); If desired, can convert formula I or compound (IA) to R 1Part is not the another kind of formula I of hydroxyl or compound (IA); And if desired, can be with formula I or compound salify (IA); And if desired, can with formula I or (IA) isomer mixture of compound be separated into single isomer.
Perhaps, formula I or compound (IA) can directly obtain single isomer by Stereoselective ground directional synthesis method.
The compound and the reaction between the chloromethyl cyanide of formula II can be finished by following steps, in the dichloromethane solution of the boron trichloride that is stirring, add the solution of formula II compound in dry-out benzene, add chloro acetonitrile and aluminum chloride then, the mixture of gained was refluxed 20 hours.
Reaction between the compound of formula III and the kharophen propanedioic acid sodium salt can be undertaken by following step: add acetamino diethyl malonate (being dissolved in the ethanol) in the alcoholic acid sodium solution, the compound that adds formula III then, reaction mixture was placed 20 hours, then in 40 ℃ of heating 4 hours in room temperature.
The compound of formula IV and the reaction between the concentrated hydrochloric acid for example can be carried out as follows: the compound of formula IV was refluxed in concentrated hydrochloric acid 7 hours.
R wherein 1Not the formula I of hydroxyl or compound (IA), the method that can know altogether according to those of ordinary skill in the art, by R as defined above and R 1The formula I of hydroxyl or compound (IA) are made initiator and are prepared.
Formula I or compound salify (IA) can be carried out in accordance with known methods; Normally implement by compound of the present invention and an amount of salt-forming reagent reacted.
As above-mentioned, in formula I or the compound (IA) unsymmetrical carbon is arranged, so these compounds can exist with the racemization mixed form, also may exist with single optical isomer (diastereomer) form.Thereby these compounds can synthesize as the form of mixture earlier, by ordinary method desired isomer separation are come out then, or synthesize by known steroselectivity method.
Being separated into single optical isomer from corresponding racemic mixture for example can carry out as follows: according to method well known in the prior art; use suitable amino acid blocking group; as ethanoyl, carbonyl carbobenzoxy-(Cbz) or tertbutyloxycarbonyl, with racemic formula I or (IA) compound convert the compound of N-protected to.Then with the derivative of the N-protected of the racemic compound of resulting formula I or formula (IA); with suitable optically active amines such as Alpha-Methyl benzylamine; brucine or cinchonine; behind salify in the presence of appropriate solvent such as the ethyl acetate Huo diox; carry out recrystallization again; obtain the formula I or (IA) salt of the pure diastereomer of a kind of mapping of compound; use the currently known methods deprotection then, and obtain formula I or (IA) (R) that take apart or (S) enantiomorph of compound.
Perhaps also can directly obtain the formula I or (IA) single enantiomer of compound by Stereoselective ground directional synthesis method.
For example, with the compound of formula (V),
Figure 941905837_IMG13
(wherein R is halogen, C 1-C 6Alkyl, C 5-C 7Cycloalkyl, phenyl-C 1-C 4Alkyl, C 1-C 6Alkoxyl group, C 6-C 10Aryloxy, phenyl-C 1-C 4Alkoxyl group or trifluoromethyl;
R 2Be COR 3Or COOR 3, R wherein 3Be C 1-C 6Alkyl)
React with formula (VIA) or compound (VIB),
Figure 941905837_IMG14
(R wherein 2By defining in formula (V) compound) then the compound of gained is hydrolyzed with suitable hydrolytic reagent such as HCl or HBr, obtain wherein R as defined above and R 1Be the formula I of hydroxyl or (IA) the pure enantiomorph of compound.
By standard operation well known to those skilled in the art, can be with R 1Be the formula I of hydroxyl or (IA) the pure enantiomorph of compound convert substituent R to 1Be the formula I of hydroxyl or another kind of compound (IA).
Formula (V) compound and formula (VIA) or (VIB) reaction between the compound for example can finish by following method, (in the presence of dibenzalacetone two palladiums (O)-chloroform adducts, reactant mixed and carry out as three at suitable palladium mixture.
The compound of formula (V) can be by the known method preparation of prior art (J.Org.Chem.1979,44,1133).
Formula (VIA) or compound (VIB) can be by prior art currently known methods preparations (J.Org.Chem.1988,53,6138).
C in formula (VIA) or the compound (VIB) 1-C 6The connotation of alkyl and formula I or (IA) identical in the compound.
Perhaps, also can directly obtain the enantiomorph of compound pure formula I or (IA), for example, by with formula I or racemic compound (IA) or and response derivative, with suitable optically pure amine, as (R)-(-)-or (S)-(+)-2-amino-2 phenylethyl alcohol, in appropriate solvent such as dimethyl formamide (DMF) as react under 5 ° to 25 ℃ temperature, the reaction times can be as between 1 hour to 48 hours.Resulting diastereomer can obtain pure epimer (being only conformation difference on an asymmetric center of diastereomer) by the chromatography separation, this product is hydrolyzed through suitable hydrolytic reagent such as HCl or HBr, and obtains the compound of formula I or enantiomer-pure (IA).
In compound of the present invention synthetic, be the compound that can be purchased as the aniline of the replacement that is equivalent to the formula II compound of initiator, or be prepared by method well known to those skilled in the art.
Formula I or compound (IA) can be with following test A in the efficient that suppresses kynurenine aminotransferase (KAT)), B), C) show.
A) the active mensuration that suppresses of KAT in the murine brain homogenate
KAT measures (Measurement of rat brain kynurenine amino-transferase at physiological kynurenine concenrtrations with the method that OKuno et al. describes in detail, J.Neurochem., 57,533-540,1991).In brief, animal is by sacrificed by decapitation, then with the cerebral tissue homogenize (1:5v/w is at 5mMTris-acetic ester damping fluid, among the pH8.0, contain 10mM2-mercaptoethanol and 50 μ m pyridoxals-5 '-phosphoric acid) and at 2 μ m[ 3H] KYN(30 n Ci), 1mM2-ketoisocaproic and 70 μ M pyridoxals-5 '-the phosphoric acid existence is following, in 150nMTris-acetic ester pH of buffer 8.0, cultivated 2 hours in 37 ℃.This reaction stops by adding trichoroacetic acid(TCA).
New synthetic [ 3H] KYNA on Dowex 50 W cationic exchange coloums by [ 3H] separate among the KYN, and quantitative with the liquid scintillation Zymography.10 minutes tissue of heated and inactivated has carried out blank in boiling water by using.
When testing under these conditions, compound of the present invention can suppress the activity of KAT.
With formula I that can the representative amount or (IA) compound and the results are shown in the following table of obtaining:
Table 1
Figure 941905837_IMG15
Nc=does not calculate
B) measure the inhibition that KYNA is produced by the rat tissue section
According to routine, the section (1 * 1mm that obtains from pallium; Heavy ≈ 1.5mg/ sheet) separating on ice, changes over to then (10/ware) in the culture dish, contain Krebs-Ringer damping fluid (NaCl, the 118.5mM of the oxidation of 1ml in this culture dish; KCl, 4.75mM; CaCl 2, 1.77mM; MgSO 4, 1.18mM; NaH 2PO 4, 12.9mM; NaH 2PO 4, 3mM; Glucose, 5mM; PH7.4).Then, in the presence of 50 μ M L-KYN, in the water-bath of jolting, this is organized in 37 ℃ of pre-down cultivations 10 minutes, cultivates 2 hours at 37 ℃ then again in oxygen room.As requested, compound of the present invention is included in the culture.After the cultivation, rapidly culture dish is placed on ice, will cut into slices apace and separate with substratum.In order to measure KYNA, the media samples of 1ml be impregnated in the boiling water bath 10 minutes, centrifugal then (8.730 * g, 10 minutes) remove sedimentary protein.(1:1 v/v), and is added to Dowex 50 W(Hydrogens to supernatant liquor, and Sigma) cationic exchange coloum is (on 0.5 * 2cm) with 0.2M HCl dilution.Then, with the 0.1M HCl of 1ml and this post of water washing of 1ml, the part that contains KYNA is come out with the water elution of 2ml.Elutriant is added to 3-μ m C 18The HPLC post (100 * 3.2 internal diameters, Bioanalytical Systems, West Lafayette, IN, U.S.A), KYNA is with containing the speed wash-out of the moving phase of 50mM ammonium acetate and 5% methyl alcohol with 0.5ml/min, and under this condition, ≈ is 7 minutes during the reservation of KYNA.
Record data and be connected to the 160UV that places 340nm absorb monitor (Beckman Instruments, Berkeley, CA, Hewlett-Packard 3390A totalizing instrument U.S.A) calculates.
In this test, tested with formula I or compound (IA) that code name is represented, the results are shown in Table 2 for gained.
Table 2
Figure 941905837_IMG16
*Do not calculate at 300 μ m nc=
Used abbreviation in table 1 and the table 2: Me, Et, n-Pr, i-Pr be represent methylidene, ethyl, n-propyl and sec.-propyl respectively.
C) use the partial purification zymin carry out dynamic analysis KAT inhibitor (Brain Research, 534,37-44(1990).
In the reaction mixture of 0.1ml cumulative volume, contain useful unlabelled KYN be diluted to ultimate density be 2 μ m [ 3H] KYN(30 nCi), 1mM pyruvate salt, 70 μ m pyridoxals-5 '-phosphoric acid, 150mM Tris-acetate buffer pH8.0 and partially purified zymin.If desired, test-compound is included in the culturing mixt, and this reaction begins by adding pyruvate salt, at 37 ℃ of 50%(w/w that add 14 μ l after cultivating 2 hours) trichoroacetic acid(TCA) and make reaction terminating.Then, add the 0.1M HCl of 1ml, and metaprotein is removed with centrifugal 4 minutes of Beckman52B microcentrifuge.The supernatant liquor of the gained of 1ml is added in Dowex 50 W post (0.5 * 1.0cm; H +Type) on,, uses the distilled water wash of 1ml then earlier with the 0.1M HCl washing of 1ml.[ 3H] the KYNA distilled water wash-out of 2ml, and quantitative with liquid phase scintillation spectrum analytical method.The enzymatic determination triplicate, blank is by 10 minutes zymin of heated and inactivated is carried out in boiling water bath.
Dynamic test is to use above-mentioned standard K AT method, and under the condition that exists at the test-compound that is with or without fixed concentration, the concentration that changes the KYN between 2 μ m to 2mM is carried out.With twice multiple point mapping, determine best curve by linear regression analysis.
Kinetic constant:
L-kynurenine D, L-5-Cl, kynurenine
Km Ki
369μM 88μM
The present invention also comprises some pharmaceutical compositions in its scope, any possible isomer and mixture of isomers that said composition contains the active substance of the formula I for the treatment of significant quantity or compound (IA) or its medicinal acceptable salt and formula I or (IA) comprises, one or more medicinal acceptable carriers, thinner or vehicle that it is relevant.
Mammals as the people, is that available medicinal compositions of the present invention is treated.
Compound of the present invention can pass through conventional route, parenteral admin for example, as by intravenous injection or transfusion, intramuscularly, subcutaneous, partial or oral or other pass through the suitable form administration that sucks or be blown into.Dosage depends on patient's age, body weight and condition, the effectiveness of compound and route of administration.For example, for the grownup, active matter quality was 0.1 to 100mg during suitable application dosage was every dose, took every day 1～4 time.Medicinal compositions of the present invention prepares as follows usually and uses with medicinal acceptable form.For example the solution of intravenous injection or the transfusion carrier that can contain is a sterilized water, or the salt brine solution of preferably aseptic isotonicity.
The suspension agent of intramuscularly, solution or emulsion can contain: with the medicinal acceptable carrier of active compound, for example, sterilized water, sweet oil, ethyl oleate, dibasic alcohol such as propylene glycol and an amount of if necessary lidocaine hydrochloride.
Can contain other pharmaceutical formulation such as suspending agent, stablizer and/or dispersion agent in the prescription of injection.
Perhaps, activeconstituents can be with Powdered preparation, before use with suitable carriers such as aseptic pyrogen-free water and constitute.In the topical application preparation, during as creme, lotion, paste, activeconstituents can mix with butyraceous or emulsive carrier commonly used.
Solid orally ingestible as tablet and capsule, can contain with active substance: thinner, for example lactose, glucose, sucrose, Mierocrystalline cellulose, W-Gum and potato starch; Lubricant is silica, talcum powder, stearic acid, Magnesium Stearate or calcium for example, and/or polyoxyethylene glycol; Wedding agent, for example, starch, gum arabic, gelatin, methylcellulose gum, carboxymethyl cellulose, polyvinylpyrrolidone; Depolymerizing agent, for example starch, alginic acid, alginate, sodium starch glycol; Effervescent mixture; Tinting material; Sweeting agent; Wetting agent, for example Yelkin TTS, Spheron MD 30/70, laurilsulfate; And, common inert material on employed nontoxic, the medicine in the pharmaceutical preparation.Described pharmaceutical preparation can be prepared according to currently known methods, for example by methods such as mixing, granulation, compressing tablet, sugar coating or coatings.
Tablet is also to carry out dressing with methods known in the art.
The preparation of liquid oral form, for example, suspensoid, syrup or liquor can be according to a conventional method, for example, with medicinal acceptable additive, sanitas, sweeting agent/or seasonings and preparing.
Medicinal compositions of the present invention can be made some formulation by method well known in the art, make this medicinal compositions be applied to the patient after, its activeconstituents can or fast or continue or discharge lentamente.
Following embodiment but does not limit the present invention in order to explanation the present invention.
Embodiment 1
5-chloro-2 amino-alpha-chloro phenyl methyl ketone
Under nitrogen atmosphere, temperature is that (100ml 1M drips 4-chloroaniline (12.12g, dry-out benzene solution (120ml) 0.095mol) in 0.1mol) to the dichloromethane solution of the boron trichloride that is stirring under 5 ℃ to 10 ℃ the condition.
In the mixture of gained, add successively the chloro acetonitrile (7.72ml, 0.115mol) and aluminum chloride (13.33g, 0.1mol).Then, this mixture was refluxed 20 hours.
After the cooling, add ice-cooled 2N hydrochloric acid (≈ 100ml), form a kind of yellow mercury oxide, mixture is under agitation in 80 ℃ of heating, up to resolution of precipitate (≈ 45 ').
Cooled solution makes pH transfer to 2 by adding 2N NaOH, and with dichloromethane extraction (three times).
Organic phase washes with water, dry then (Na 2SO 4), and concentrate.
Residue grinds with hexane (≈ 120ml), obtains the required light brown solid product of 9.27g, m.p.133-136 ℃.
According to similarity method, can make following compounds:
5-methyl-2-amino-alpha-chloro phenyl methyl ketone, m.p.127～129 ℃;
5-fluoro-2-amino-alpha-chloro phenyl methyl ketone, m.p.121～123 ℃;
5-ethyl-2-amino-alpha-chloro phenyl methyl ketone, m.p.118～120 ℃;
5-cyclohexyl-2-amino-alpha-chloro phenyl methyl ketone, m.p.88～91 ℃;
5-bromo-2-amino-alpha-chloro phenyl methyl ketone, m.p.127～130 ℃;
5-n-propyl-2-amino-alpha-chloro phenyl methyl ketone, m.p.119～122 ℃;
5-sec.-propyl-2-amino-alpha-chloro phenyl methyl ketone, m.p.66～70 ℃.
Embodiment 2
Acetylaminohydroxyphenylarsonic acid (2-amino-5-chlorobenzoyl methyl) malonic ester
(1.04g 0.0453mol) is dissolved in the ethanol (80ml), and (9.84g, 0.0453mol) at 120ml alcoholic acid solution, this solution was 45 ℃ of heating 1 hour to add acetamino diethyl malonate with sodium.
After being cooled to room temperature, (9.25g 0.0453mol) at 150ml alcoholic acid solution, stirs under nitrogen atmosphere simultaneously Dropwise 5-chloro-2-amino-alpha-chloro phenyl methyl ketone.
With reactant stirring at room 20 hours, then with this mixture 40 ℃ of heating 4 hours.Reaction mixture is evaporated to dried, residue 300ml water dissolution, and add 1N NaOH(20ml), use extracted with diethyl ether.
Organic phase washes with water, and is dry and be evaporated to driedly, obtains solid, obtains the required paste solid product of 6.02g with 210ml Virahol recrystallization, m.p.156～158 ℃.
According to similar methods, can prepare following compounds:
Acetylaminohydroxyphenylarsonic acid (2-amino-5-toluyl methyl)-diethyl malonate, m.p.179～181 ℃;
Acetylaminohydroxyphenylarsonic acid (2-amino-5-fluoro phenacyl)-diethyl malonate, m.p.143～145 ℃;
Acetylaminohydroxyphenylarsonic acid (2-amino-5-ethylbenzoyl methyl)-diethyl malonate, m.p.121～123 ℃;
Acetylaminohydroxyphenylarsonic acid (2-amino-5-cyclohexyl phenacyl)-diethyl malonate, m.p.89～93 ℃;
Acetylaminohydroxyphenylarsonic acid (2-amino-5-bromo phenacyl)-diethyl malonate, m.p.151～154 ℃;
Acetylaminohydroxyphenylarsonic acid (2-amino-5-n-propyl phenacyl)-diethyl malonate, m.p.115～117 ℃; With
Acetylaminohydroxyphenylarsonic acid (2-amino-5-sec.-propyl phenacyl)-diethyl malonate, m.p.110～115 ℃.
Embodiment 3
2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (D, L-5-chloro-kynurenine)
(5.3g, 0.01377mol) solution at concentrated hydrochloric acid (60ml) refluxed 7 hours with acetylaminohydroxyphenylarsonic acid (2-amino-5-chloro phenacyl) diethyl malonate under stirring.
Reactant vacuum-evaporation is to doing, and the residue water dissolution is used washed with dichloromethane.
Water is concentrated, in the residue water-soluble (100ml), gained solution is transferred to 6.5 and obtain required yellow mercury oxide product with 2N NaOH with pH.
Filter, the washing solid obtains the required product of 3.10g, m.p.236～238 ℃ (decomposition).
According to similar method, can prepare following compounds:
2-amino-4-(2-amino-5-aminomethyl phenyl)-4-oxo-butyric acid, m.p.230～250 ℃ (decomposition);
2-amino-4-(2-amino-5-fluoro phenyl)-4-oxo-butyric acid, m.p.200～225 ℃ (decomposition);
2-amino-4-(2-amino-5-ethylphenyl)-4-oxo-butyric acid, m.p.210 ℃ (decomposition);
2-amino-4-(2-amino-5-cyclohexyl phenyl)-4-oxo-butyric acid, m.p.230～250 ℃ (decomposition);
2-amino-4-(2-amino-5-bromo phenyl)-4-oxo-butyric acid, m.p.233 ℃ (decomposition);
2-amino-4-(2-amino-5-n-propyl phenyl)-4-oxo-butyric acid, m.p.233～234 ℃ (decomposition);
2-amino-4-(2-amino-5-isopropyl phenyl)-4-oxo-butyric acid, m.p.235 ℃ (decomposition).
Embodiment 4
The method of taking apart by diastereomeric salt prepares (S) (-)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (L-5-chloro kynurenine) and
(R)-(+)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (D-5-chloro kynurenine)
To the 2-amino that is stirring-4-(2-amino-5-chlorophenyl)-the 4-ketobutyric acid (5.23g, 21.55mmol), NaHCO 3(3.98g, 47.4mmol) and Na 2CO 310H 2O(6.16g, 21.55mmol) in the solution of 300ml water, drip under the room temperature diacetyl oxide (2.236ml, 23.7mmol).
With solution stirring 1 hour, be acidified to pH5 with 2N HCl, with ethyl acetate extraction (4 times), washing, dry and evaporation is to obtain a light yellow solid.
This crude product grinds with hexane, obtains 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-4-ketobutyric acid (4.20g; 68.4%; M.p.187-190 ℃).
To the 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl that stirs)-4-ketobutyric acid (4.20g 14.75mmol) in 500ml95% alcoholic acid solution, drips R-(+)-Alpha-Methyl benzylamine (1.88ml, 14.75mmol).After 20 minutes, solvent evaporation is fallen, residue obtains solids (5.10g with the ether development; M.p.130～150 ℃; [α] 20 D=+2.5 ° (1%, CH 3OH).
With re-crystallizing in ethyl acetate four times, obtain 1.12g(enantiomorph yield 37%) 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-salt of 4-oxo-butyro-(-)-Alpha-Methyl benzylamine (m.p.154.5～156 ℃; [α] 20 D=-60.8 ° (1%, CH 3OH).
(1.12g 2.76mmol) in the solution of ethyl acetate (100ml), adds entry (20ml) and 1N HCl(2.9ml, 2.9mmol) to (-)-Alpha-Methyl benzylamine salt of vigorous stirring.After 30 minutes, tell organic phase, the water ethyl acetate extraction.The organic phase that merges washes with water, dry and evaporation and obtain light brown (-)-2-alpha-acetamido--4-(2-amino-5-chlorophenyl)-4-ketobutyric acid (0.76g; 97%) solid (m.p.182～183.5 ℃ (decomposition); [α] 20 D=-88.7 ° (1%, CH 3OH).
With (-)-2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-solution in 4-oxo-butyric acid (0.76g is 2.67mmol) at 2N HCl(90ml), heating is 3 hours under reflux temperature, and this aqueous solution evaporate is to doing, soluble in water with residue, uses CH 2Cl 2Washing and revaporization.With transferring pH to 6.5 in the residue water-soluble (30ml) and with 1N NaOH, separate out the faint yellow solid thing.This solid filtering is also used cold water washing, obtains (R)-(+)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (0.40g; 59.7%; M.p.210～211 ℃ (decomposition); [α] 20 D=+11.5(1%, CH 3COOH; Ee=96%).
To prepare (-)-Alpha-Methyl benzylamine salt process in the mother liquor of gained mix and evaporation, obtain 4.9g(12mmol) solid.Mixture and 400ml ethyl acetate that should (-) and (+) salt, 80ml water and 1N HCl(12.6ml, 12.6mmol) vigorous stirring together.After 30 minutes, tell organic phase, the water ethyl acetate extraction.The organic phase that merges washes with water, and drying is also evaporated, and is rich in the 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl of (+) enantiomorph)-4-oxo-butyric acid (light brown solid) (3.41g; 100%; M.p.172～178 ℃).
To the 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl that is stirring)-4-oxo-butyric acid (3.41g, 11.97mmol) in 400ml95% alcoholic acid solution, dropping (S)-(-)-Alpha-Methyl benzylamine (1.52ml, 11.97mmol).After 20 minutes, solvent evaporated.Carry out obtaining 1.49g(61.3% behind three recrystallizations with ethyl acetate) 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-4-oxo-butyro-(+)-Alpha-Methyl benzylamine salt (m.p.154.5～155.5 ℃); [α] 20 D=+60.9(1%, CH 3OH).
1.49g above-mentioned salt by above-mentioned, the method that is used for prepare (-) enantiomorph is carried out, and obtains 1.03g(98.5%) (+)-2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (m.p.179～180 ℃, decomposition); [α] 20 D=+89.0(1%, CH 3OH).
In order to prepare (R) enantiomorph, use as stated above (+)-2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid makes initiator, obtains 0.65g(71.4%) (S)-(-)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (m.p.208～209 ℃ (decomposition); [α] 20 D=-12.6 ° (1%, CH 3COOH, ee=96%).
Embodiment 5
Select synthetic method preparation (S)-(-)-2-amino-4-(2-amino-5-chlorophenyl by enantiomorph)-4-oxo-butyric acid (L-5 chloro kynurenine) and (R)-(+)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (D-5-chloro kynurenine).
Under nitrogen atmosphere, with ice bath cooling 4-chloro-N-pivalyl aniline (2.11g, 10mmol) solution in the 30ml anhydrous tetrahydro furan.Drip then 1.6M n-Butyl Lithium (15.625ml, hexane solution 25mmol), 0 ℃ stir 2.5 hours after, (2.19g 11mmol) is dissolved in the solution of anhydrous tetrahydro furan (8ml) to add the chlorination trimethyl tin in 0 ℃ in 20 minutes.Then this reactant was stirred 2 hours at 0 ℃, in stirring at room 16 hours, water quenching, and use the salt water washing of ethyl acetate extraction, organic phase, drying also is concentrated into dried.Residue on silicagel column with sudden strain of a muscle formula chromatography purification (diisopropyl ether: 40 °/70 ° of sherwood oils=10:23), obtain the white solid of 3.1g4-chloro-2-trimethylammonium stannyl-N-pivalyl aniline, (82.9%, m.p.169～172 ℃).
＊Joc44，1133（1979）
With 4-chloro-2-trimethylammonium stannyl-N-valeryl aniline (1.6g, 4.2mmol) and (S)-(1.25g 42mmol) is dissolved in the dry toluene (50ml) 3-carbobenzoxy-(Cbz)-5-oxo-4-oxazolidine Acetyl Chloride 98Min..In this solution, add Pd 2(dba) 3CHCl 3(40.5mg), this mixture was 70 ℃ of heating 8 hours.After the mixture cooling, remove catalyzer by diatomite filtration, filtrate concentrates, and dilutes with ethyl acetate then; The solution of gained is successively with saturated supercarbonate, water and saturated NaCl washing, dry then and evaporation.Residue on silicagel column with sudden strain of a muscle formula chromatography purification (ethyl acetate: hexane=8:30), obtain (S)-(+)-N-pivalyl-2-[1-oxygen-2-[3-(carbobenzoxy-(Cbz))-5-oxo-oxazolidines-4-yl]-ethyl]-the clear crystal 1.06g(53.5% of 4-chloroaniline); M.p.113～116 ℃; [α] 20 D=-114.5(1%, ethyl acetate).
＊JOC53，6138（1988）。
With (S)-(+)-N-pivalyl-2-[1-oxygen-2-[3-(carbobenzoxy-(Cbz) that is stirring)-5-oxygen-oxazolidines-4-yl] ethyl]-4-chloro aminobenzen (1.06g, 2.24mmol), 37%HCl(20ml), H 2O(20ml) and CH 3COOH(28ml) mixture to doing, in the residue water-soluble (30ml), is used CH with this solution evaporation in 70 ℃ of heating 5.5 hours 2Cl 2Sudden strain of a muscle formula chromatography purification (chloroform: methyl alcohol: 30%NH is used in washing and evaporation once more, crude product on silicagel column 4OH=140:60:6), obtain (S)-(-)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyro-yellow crystal (0.29g; 51.5%; M.p.206～208 ℃; [α] 20 D=-12.0 ° (1%; CH 3COOH); Ee=96%).
By similar approach, can prepare:
(R)-(+)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (D-5-chloro kynurenine); [α] 20 D=+11.5 ° (1%, CH 3COOH).
Embodiment 6
Formation by diastereomer and chromatographic separation preparation (S)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (L-5-chloro kynurenine) and (R)-(+)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid (D-5-chloro kynurenine).
Under the nitrogen atmosphere, in the time of 5～8 ℃, to the 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl-4-oxo-butyric acid (0.569g that is stirring; 2mmol) at no DMF(8ml) solution in, add 1,1 in batches '-carbonyl dimidazoles (0.34g; 2.1mmol).After 1.5 hours, in the time of 3～5 ℃, drip the 2-of (R)-(-) amino-2 phenylethyl alcohol (0.33g 5 ℃ of stirrings; 2.4mmol) solution in dry DMF (6ml).Then reactant was stirred in ice bath 2 hours, stirring at room 16 hours, water quenching and use ethyl acetate extraction then.Organic phase washes with water, uses anhydrous sodium sulfate drying, and is concentrated into dried.Residue is through flash silica gel column chromatography purification (ethyl acetate: methyl alcohol=98:2), and obtain 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-N-(2-hydroxyl-1-phenylethyl)-yellow solid (0.18g of 4-oxo butyramide; 22%; M.p.212～215 ℃) (pure diastereomer R fSmaller).
With 2-acetylaminohydroxyphenylarsonic acid 4-(2-amino-5-chlorophenyl)-N-(2-hydroxyl-1-phenyl-ethyl)-4-oxo-butyramide (pure diastereomer R fSmaller) (0.155g; 0.383mmol) at 2N HCl(15ml) and in solution, reflux 6 hours, to doing, residue is soluble in water, uses CH with this solution evaporation 2Cl 2Washing and revaporization, 30% ammonia soln=140:60:6), obtain (S)-(-)-2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyro-yellow solid (0.048g crude product is through flash silica gel column chromatography purification (chloroform: methyl alcohol:; 50%, m.p.205～208 ℃; [α] 20 D=-12.0 ° (1%, CH 3COOH).
According to similarity method, can prepare following compounds:
(R)-(+)-2-amino-4-(2-amino-5-chloro-phenyl-)-4-oxo-butyric acid (D-5-chloro kynurenine); [α] 20 D=+11.5 ° (1%, CH 3COOH).
Embodiment 7
Orally administered tablet
Tablet can make by known method such as direct compression process or wet granulation process.
For example, every heavy 0.250g and the tablet that contains the 50mg active substance can make as follows:
Form (10,000):
2-amino-4-(2-amino-5-chloro-phenyl-)-4-oxy butyrate 500g
Lactose 1400g
W-Gum 500g
Talcum powder 80g
Magnesium Stearate 20g
With 2-amino-4-(2-amino-5-chloro-phenyl-)-W-Gum of 4-ketobutyric acid, lactose and half amount mixes, and mixture is pressed through 0.5mm purpose sieve.W-Gum (10g) is suspended in the warm water (90ml), and the slurries of gained are used for powder is granulated, and the grain that drying is made is crossed the 1.4mm mesh sieve, adds remaining starch, talcum powder and Magnesium Stearate then, carefully mixes compressing tablet then.
The tablet of other dosage can make by the ratio of regulating active substance and assistant agent.
Embodiment 8
Orally administered capsule
Every inclusion is that 0.200g and the capsule that contains the 20mg active substance can make as follows: the composition of 500 capsules:
2-amino-4-(2-amino-5-chloro-phenyl-)-4-oxo-butyric acid 10g
Lactose 80g
W-Gum 5g
Magnesium Stearate 5g
Above-mentioned substance is packed in the biplate hardness gelatine capsule into the heavy 0.200g of the content of every capsules.
Embodiment 9
Intramuscularly agent 25mg/ml
Medicinal composition for injections can make by following method, with 2-amino-4-(2-amino-5-chlorophenyl of 25g)-4-oxo-butyro-sodium salt is dissolved in the water for injection (100ml) and makes injection liquid, be encapsulated in then in the ampoule of 1～5ml.

Claims (8)

1, as the use of a compounds of kynurenine aminotransferase (KAT) inhibitor, this compounds be used for the treatment of with old and feeble relevant knowledge knows obstacle and term brain function lack of proper care.
2, according to the use of claim 1, wherein the compound as kynurenine aminotransferase (KAT) inhibitor is the compound with logical formula I, its individual isomer or its mixture of isomers, and medicinal acceptable salt.
Figure 941905837_IMG2
Wherein R is halogen, C 1-C 6Alkyl, C 5-C 7Cycloalkyl, phenyl-C 1-C 4Alkyl, C 1-C 6Alkoxyl group, C 6-C 10Aryloxy, phenyl C 1-C 4Alkoxyl group or trifluoromethyl;
R 1Be hydroxyl, C 1-C 6Alkoxyl group, amino, single C 1-C 6Alkylamino, two-C 1-C 6Alkylamino, hydroxyl amino, C 1-C 4Alkoxy amino or benzyloxy amino.
3, the compound of formula (IA), its individual isomer or its mixture of isomers, and medicinal acceptable salt,
Wherein R is halogen, C 1-C 6Alkyl, C 5-C 7Cycloalkyl, phenyl-C 1-C 4Alkyl, C 1-C 6Alkoxyl group, C 6-C 10Aryloxy, phenyl C 1-C 4Alkoxyl group or trifluoromethyl;
R 1Be hydroxyl, C 1-C 6Alkoxyl group, amino, single C 1-C 6Alkylamino, two-C 1-C 6Alkylamino, hydroxyl amino, C 1-C 4Alkoxy amino or benzyloxy amino,
Condition is:
(ⅰ) work as R 1Be that then this halogen was not a fluorine when hydroxyl and while, R was halogen;
(ⅱ) work as R 1Be that hydroxyl and while R are C 1-C 6During alkyl, this C then 1-C 6Alkyl is not a methyl.
4, according to the compound of the general formula (IA) of claim 3, its individual isomer or its mixture of isomers, and medicinal acceptable salt,
Wherein R is a halogen, C 1-C 6Alkyl or C 5-C 7Cycloalkyl;
R 1Be hydroxyl,
Condition is:
(ⅰ) when R is halogen, then this halogen is a fluorine not;
(ⅱ) when R be C 1-C 6During alkyl, this C then 1-C 6Alkyl is not a methyl.
5, be selected from following compound, its individual isomer or its mixture of isomers, and medicinal acceptable salt:
2-amino-4-(2-amino-5-chlorophenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-ethylphenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-bromo phenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-n-propyl phenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-isopropyl phenyl)-4-oxo-butyric acid;
2-amino-4-(2-amino-5-cyclohexyl phenyl)-4-oxo-butyric acid.
6, the compound of defined formula I compound of a kind of preparation claim 2 or the defined formula of claim 3 (IA), or the method for its medicinal acceptable salt, this method comprises:
1) makes the compound of formula II and chloro acetonitrile reaction and obtain the compound of formula III
Figure 941905837_IMG4
Wherein R in the claim 2 in formula I or claim 3 Chinese style (IA) definition,
Figure 941905837_IMG5
Wherein the R definition as above.
2) make the sodium salt reaction of the compound and the kharophen propanedioic acid of formula III, and generate the compound of formula IV
Figure 941905837_IMG6
Wherein the R definition as above.
3) the formula IV compound of above-mentioned definition is handled with concentrated hydrochloric acid, generated formula I or compound (IA), wherein R defines as above, R 1Be hydroxyl, and if desired, can change into R to formula I or compound (IA) 1Part is not (I) of hydroxyl or other compound (IA); And if desired, can be with formula I or the different conversion salify of compound (IA), and if desired, can with formula I or (IA) isomer mixture of compound be separated into single isomer.
7, a kind of medicinal compositions, said composition contain the formula I compound of the claim 2 for the treatment of significant quantity or according to the compound of the formula (IA) of claim 3, or its medicinal acceptable salt, and medicinal acceptable carrier, thinner or vehicle.
8, according to the medicinal compositions of claim 7, it is used for the treatment of old and feeble relevant knowledge and knows obstacle and brain function imbalance in term.
CN94190583A 1993-08-06 1994-07-15 Substituted kynurenines, a process for their preparation, and use as medicaments Pending CN1113386A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/102,843 US5519055A (en) 1993-08-06 1993-08-06 Substituted kynurenines and process for their preparation
US08/102,843 1993-08-06

Publications (1)

Publication Number Publication Date
CN1113386A true CN1113386A (en) 1995-12-13

Family

ID=22291962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94190583A Pending CN1113386A (en) 1993-08-06 1994-07-15 Substituted kynurenines, a process for their preparation, and use as medicaments

Country Status (15)

Country Link
US (2) US5519055A (en)
EP (2) EP0919538A1 (en)
JP (1) JPH08502523A (en)
CN (1) CN1113386A (en)
AT (1) ATE181728T1 (en)
AU (1) AU680672B2 (en)
CA (1) CA2145178A1 (en)
DE (1) DE69419306D1 (en)
FI (1) FI951631A (en)
HU (1) HUT70394A (en)
IL (1) IL110563A (en)
PL (1) PL308237A1 (en)
TW (1) TW408099B (en)
WO (1) WO1995004714A1 (en)
ZA (1) ZA945830B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330774C (en) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 Kynurenine hydrolase polymorphism and its diagnostic use
CN103228660A (en) * 2010-12-01 2013-07-31 辉瑞大药厂 Kat II inhibitors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521486D0 (en) * 1995-10-20 1995-12-20 Pharmacia Spa Fluoro-substituted benzoylpropionic acid derivatives
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522615D0 (en) 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9618349D0 (en) * 1996-09-03 1996-10-16 Pharmacia Spa N-substituted 2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibitory activity
GB9725055D0 (en) * 1997-11-26 1998-01-28 Pharmacia & Upjohn Spa 1,3,4-thiadiazoles compounds
ITMI20041626A1 (en) * 2004-08-06 2004-11-06 Roberto Pellicciari QUINURENIN-AMINO-TRANSFERASE INHIBITORS
WO2007064784A1 (en) * 2005-11-30 2007-06-07 The University Of Maryland, Baltimore Inhibitors of kynurenine aminotransferase and uses therefor
US9834801B2 (en) 2013-03-14 2017-12-05 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
CA2946702C (en) * 2014-04-23 2022-06-28 Mitsubishi Tanabe Pharma Corporation Bicyclic or tricyclic heterocyclic compound
US10793582B2 (en) 2015-10-22 2020-10-06 Mitsubishi Tanabe Pharma Corporation Bicyclic heterocyclic compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE168989T1 (en) * 1991-02-28 1998-08-15 Merrell Pharma Inc NMDA ANTAGONISTS
US5495044A (en) * 1991-04-18 1996-02-27 University Of Georgia Research Foundation, Inc. Inhibitors of kynureninase
JPH06510023A (en) * 1991-04-18 1994-11-10 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド Inhibitors of kynureninase
IT1265101B1 (en) * 1993-07-23 1996-10-30 Erba Carlo Spa DERIVATIVES OF 2-AMINO-4-PHENYL-4-BUTYRIC BONE ACID

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330774C (en) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 Kynurenine hydrolase polymorphism and its diagnostic use
CN103228660A (en) * 2010-12-01 2013-07-31 辉瑞大药厂 Kat II inhibitors

Also Published As

Publication number Publication date
PL308237A1 (en) 1995-07-24
AU680672B2 (en) 1997-08-07
AU7360294A (en) 1995-02-28
US5708030A (en) 1998-01-13
CA2145178A1 (en) 1995-02-16
FI951631A0 (en) 1995-04-05
ZA945830B (en) 1995-03-09
HUT70394A (en) 1995-10-30
EP0663899B1 (en) 1999-06-30
WO1995004714A1 (en) 1995-02-16
TW408099B (en) 2000-10-11
IL110563A0 (en) 1994-11-11
DE69419306D1 (en) 1999-08-05
EP0663899A4 (en) 1996-01-17
HU9500997D0 (en) 1995-06-28
EP0663899A1 (en) 1995-07-26
ATE181728T1 (en) 1999-07-15
IL110563A (en) 1999-04-11
JPH08502523A (en) 1996-03-19
EP0919538A1 (en) 1999-06-02
US5519055A (en) 1996-05-21
FI951631A (en) 1995-04-05

Similar Documents

Publication Publication Date Title
CN1038928C (en) Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
CN1041827C (en) Substituted 3-aminoquinuclidines
CN1065536C (en) Process and crystal form of 2-methyl -thieno -benzodiazepine
CN1812963A (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
CN1069023A (en) 4-[2-(2-hydroxyl-2-benzene ethylamino) oxyethyl group that is used for the treatment of obesity and correlation behavior] phenylacetic acid derivatives
CN1113386A (en) Substituted kynurenines, a process for their preparation, and use as medicaments
CN1390194A (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
CN1909897A (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
CN1520290A (en) Carbocyclic hydrorazino inhibitors of copper-containing amine oxidases
CN1835936A (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
CN1205328A (en) Sulfonylaminocarboxylic acids
CN1039996C (en) N-substituted azabicycloheptane derivatives, the preparation and use thereof
CN1176101A (en) N -(4 -aryl -thiazol -2 -yl) -sulphonamide derivatives and their use
CN1878781A (en) phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease
CN1095712A (en) Compounds
CN1146562C (en) Thtrahydrothiopy 2,3-diazanaphthylaone derivatives as PDE inhibitors
CN1280258C (en) Process for producing 4,5-diamino shikimic acid derivative
CN1271342A (en) Synthesis of clasto-lactacystin-beta-lactone and analogs thereof
CN1014515B (en) Nonaromatic fluoroallylamine mao inhibitors
CN1268132A (en) Cis-substituted fluoromethylpyrrolidine derivatives
CN1159312C (en) Novel poyrimidine derivatives and process for preparation thereof
CN1055472C (en) Quinolyl-one derivatives, prepn. method and application and use as medicine
CN1064075A (en) Carbamic acid derivative and preparation method thereof
CN1025786C (en) Carbamoyl derivatives
CN1856301A (en) Curable beta-amino acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Farmacia and John Earp

Applicant before: Pharmetrix Corporation

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: PHARMACIA CORPORATION TO: PHARMASILAY AND UPJOHN COMPANY

C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication